Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma

Eisuke Kobayashi, Mari Masuda, Robert Nakayama, Hitoshi Ichikawa, Reiko Satow, Miki Shitashige, Kazufumi Honda, Umio Yamaguchi, Ayako Shoji, Naobumi Tochigi, Hideo Morioka, Yoshiaki Toyama, Setsuo Hirohashi, Akira Kawai, Tesshi Yamada

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Pulmonary metastasis is the most significant prognostic determinant for osteosarcoma, but methods for its prediction and treatment have not been established. Using oligonucleotide microarrays, we compared the global gene expression of biopsy samples between seven osteosarcoma patients who developed pulmonary metastasis within 4 years after neoadjuvant chemotherapy and curative resection, and 12 patients who did not relapse.We identified argininosuccinate synthetase (ASS) as a gene differentially expressed with the highest statistical significance (Welch's t test, P = 2.2 × 10-5). Immunohistochemical analysis of an independent cohort of 62 osteosarcoma cases confirmed that reduced expression of ASS protein was significantly correlated with the development of pulmonary metastasis after surgery (log-rank test, P < 0.05). Cox regression analysis revealed that ASS was the sole significant predictive factor (P = 0.039; hazard ratio, 0.319; 95% confidence interval, 0.108-0.945). ASS is one of the enzymes required for the production of a nonessential amino acid, arginine. We showed that osteosarcoma cells lacking ASS expression were auxotrophic for arginine and underwent G0-G 1 arrest in arginine-free medium, suggesting that an arginine deprivation therapy could be effective in patients with osteosarcoma. Recently, phase I and II clinical trials in patients with melanoma and hepatocellular carcinoma have shown the safety and efficacy of plasma arginine depletion by stabilized arginine deiminase. Our data indicate that in patients with osteosarcoma, reduced expression of ASS is not only a novel predictive biomarker for the development of metastasis, but also a potential target for pharmacologic intervention.

Original languageEnglish
Pages (from-to)535-544
Number of pages10
JournalMolecular cancer therapeutics
Volume9
Issue number3
DOIs
Publication statusPublished - 2010 Mar

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma'. Together they form a unique fingerprint.

  • Cite this

    Kobayashi, E., Masuda, M., Nakayama, R., Ichikawa, H., Satow, R., Shitashige, M., Honda, K., Yamaguchi, U., Shoji, A., Tochigi, N., Morioka, H., Toyama, Y., Hirohashi, S., Kawai, A., & Yamada, T. (2010). Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Molecular cancer therapeutics, 9(3), 535-544. https://doi.org/10.1158/1535-7163.MCT-09-0774